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Summary.-A series of human bronchial-carcinoma xenografts (3 small-cell ana-
plastic, 2 large-cell anaplastic and 3 adenocarcinomas) established in immune-
suppressed mice were treated with combination chemotherapy based on clinical
regimes. Xenograft response was assessed by the in situ endpoint of growth delay
in s.c. tumours. Dose-response relationships of 3 triple-drug combinations and their
component agents were explored, allowing the relative contributions of single agents
in each combination to be assessed. The results demonstrate that the effects produced
in the xenografts were generally consistent with clinical experience. Procarbazine,
cyclophosphamide and CCNU stood out as the most effective drugs in small cell
carcinoma, but were ineffective in the other histological types.
There was some evidence for individuality of therapeutic response among the
grafts, supporting the case for incorporating panels of histologically similar xeno-
grafts into primary drug-screening programmes to complement existing syngeneic
rodent tumour systems.
IMPROVEMENTS IN RESPONSE and pro-
longation of survival have been achieved
with aggressive combination chemo-
therapy in small-cell anaplastic carcinoma
ofthe lung. Some long-term remissions are
now being obtained, but there still remains
the problem of early relapse in many
patients, with the appearance of disease
that is refractory to further chemotherapy
(Bunn et al., 1977; Livingston, 1978;
Oldham & Greco, 1980).
In contrast, there has been little
progress in the treatment of advanced
squamous, large-cell anaplastic and adeno-
carcinoma. Both single-agent and com-
bination chemotherapy are associated
with low response rates, with little evi-
dence for prolonged survival (Selawry,
1977; White & Boles, 1981).
There is an urgent requirement, there-
fore, for more satisfactory laboratory tests
to improve clinical results. The human
tumour xenograft is an exciting develop-
ment in experimental therapeutics, and
may provide a more rational approach to
the use of new and existing drugs in
combination or as single agents in the
treatment of bronchial carcinoma.
Morphology and functional activity of
human tumours in situ appear to be
largely retained when established as xeno-
grafts in nude or immune-suppressed
rodents (Ohsawa et al., 1977; Sharkey et
al., 1978; Steel, 1978; Houghton & Taylor,
1978).
Although xenografts have been found to
respond to agents which are generally
effective clinically (Povlsen & Rygaard,
1974; Kopper& Steel, 1975; Steel, 1978) we
have recently established a more precise
relationship between individual xenograft
and donor-patient responses upon which
the chemotherapeutic validity of xeno-
grafts ultimately depends. A total of 21
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separate chemotherapeuticresponsesdocu-
mented in 16 patients with bronchial
carcinoma were similar to those found in
their respective xenografts treated with
the same single agents or combinations.
Large differences were found between the
chemosensitivity of most small-cell carcin-
omas and the chemoresistance oflarge-cell
anaplastic, squamous and adenocarcino-
mas, demonstrating good parallelism
between man and mouse among the histo-
pathological categories of tumour (Short-
house et al., 1980a, b). Many ofthe patients
in this study received combination chemo-
therapy, though an ideal comparison of
xenograft and donor-patient responses
would have involved the use of a single
agent given to each patient and xenograft.
However, the adoption of single-agent
chemotherapy in patients with small-cell
carcinoma specifically for a comparative
xenograft study was considered unjusti-
fied, because of the clinical superiority of
combination chemotherapy (Bunn et al.,
1977). Xenografts were therefore also
treated with the same drug combinations
received by individual donor patients.
An evaluation of the relative contribu-
tion of component drugs within these
combinations is described in the present
report. An attempt has been made to rank
these agents in order of effectiveness
against bronchial-carcinoma xenografts of
different histologies.
MATERIALS AND METHODS
Human bronchial carcinomas were estab-
lished as s.c. xenografts in 8-10-week-old
female CBA/lac mice immune-suppressed by
neonatal thymectomy, cytosine arabinoside
and whole-body irradiation (Steel etal., 1978).
Tumour-bearingmice werehousedconvention-
ally, 5/cage, and maintained on Spratt's No. 1
Rodent Breeding Diet and acidified water ad
libitum. Specific-pathogen-free (SPF) condi-
tions, necessary for optimum maintenance of
nude mice (Giovanella & Stehlin, 1973) were
not required.
Groups of tumours in early passage (2-11)
received chemotherapy when their average
volume reached 0.2-05 cm3 (calculated by
rI/6 x mean diameter3). The parameter of
chemotherapeutic response was the in situ
endpoint of growth delay, which was deter-
mined by dividing the difference between
median volume-doubling times ofcontrol and
treated tumours by the median doubling time
of control tumours. This gave an estimate of
growth delaydue to treatment, inmultiples of
the doubling time of untreated tumours
(Kopper & Steel, 1975).
Xenografts and original donor tumours
were classified histologically according to the
Working Party for Therapy of Lung Cancer
(WP-L) classification (Matthews, 1973) and
checked at each xenograft passage. Chromo-
some analysis was performed on xenografts to
exclude the presence of syngeneic murine
tumours.
Patients with small-cell carcinoma received
cyclophosphamide (CY, 1 g/m2) and CCNU
(100 mg/M2) combined with a 24h infusion of
methotrexate (MTX, 200 mg/M2) followed by
folinic acid rescue (MCC). Two 6-week cycles
of MCC were administered in the induction
phase and then monthly courses ofvincristine
(VINCR, 1-4 mg/M2), adriamycin (ADR,
40 mg/M2) and procarbazine (100 mg/M2)
were given (VAP) for a total treatment period
of about 9 months.
Patients with inoperable or advanced large-
cell anaplastic or adenocarcinoma were
treated with monthly cycles of CY (1 g/m2),
ADR (30 mg/M2) and 5-fluorouracil (FU,
500 mg/M2) in combination given on Days 1
and 8 (CAF).
In order to parallel the clinical situation
experimentally, xenografts were given the
same combination of agents used in the
treatment of patients with similar tumour
histology.
Ideally, chemotherapeutic agents should be
given to mice in doses and schedules
equivalent to those received by patients.
However, since the question of comparative
pharmacodynamics between species is intri-
cate and data incomplete, there is at present
no satisfactory basis for converting human to
murine doses. The policy adopted was to use
the maximum tolerated dose (MTD) in the
mouse, determined by preliminary toxicity
studies (LD1o endpoint). Freireich et al. (1966)
found that an MTD of drug correlated well
from species to species on a mg/M2 basis.
In order to assess dose-response relation-
ships, combinations were given in increasing
doses up to the MTD. The dose ratio of
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component agents within a combination used
clinically was strictly maintained when
treatingthexenografts.Componentdrugswere
therefore not always at equitoxic doses within
the combinations, because their proportions
were based on clinical doses rather than equal
fractions of murine LD10 doses.
To evaluate the relative contribution of
component drugs within the MCC, VAP and
CAF combinations, in terms of cytotoxicity,
single-agent dose-response relationships were
also studied.
Clinically, combination chemotherapy was
given in repeated cycles. The xenografts,
however, were restricted to a single cycle of
treatment, which allowed tumour growth
delay to be quantified and ranked amongst
xenograft lines without interference from
subsequent cycles of treatment. Since the
doubling time, and the observable duration of
tumour growth inthe mouse is shorter than in
man, it would have been difficult to adapt a
prolonged repeated course of treatments to
the mouse, and in the case of rapidly
enlarging chemoresistant tumours, euthan-
asia of animals would have been necessary
before completion of treatments.
Schedules of drug administration within a
cycle were similar to those in patients.
However, some compromises were necessary.
For example, patients received MTX infused
i.v. over 24 h, followed by folinic acid rescue,
whereas mice were given 3 divided doses of
MTX i.p. over 24 h. No folinic acid rescue was
used in mice, because toxicity studies demon-
strated that the MTD of the MCC combina-
tion contained only40% oftheMTD ofMTX,
so that folinic acid rescue would not have
improved the survival of the animals.
Dosage and schedules for chemotherapeutic
agents given to mice are shown in Table I. All
agents weregiven i.p. in a volume of0 01 ml/g
ofmouse body weight. MTX as a single agent
or in combination was givenin 3divided doses
over 24 h, in an attempt to mimic 24h
infusion in patients. VINCR was given as a
single injection on Days 1 and5. Procarbazine
was given in 5 equal daily fractions as
single doses. All drugs were prepared in
aqueous solution with the exception of
CCNU, which was made up in 1 part 10%
dimethyl sulphoxide (DMSO) in 9 parts 5 %
Tween 80.
All agents were freshly prepared immedi-
ately before administration, with the excep-
tion of MTX which was stored at the
appropriate concentration at -2000.
Statisticalanalysis.-Chemotherapeutic res-
ponses of xenografts were expressed in terms
of median growth delay and analysed by
Friedman's 2-way analysis of variance by
ranks (Seigel, 1956).
TABLE I.-Chemotherapeutic agents in xenografts (all i.p.)
Agent
Methotrexate (MTX)
Cyclophosphamide (CY)
CCNU
5-Fluorouracil (FU)
Vincristine (VINCR)
Adriamycin (ADR)
Procarbazine
Manufacturer
Lederle
Koch-Light
Lundbeck
Roche
Eli Lilly
Mont Edison
Roche
Dose (mg/kg)
A
Single* Combinedt
100 40
(MCC)
200 200
(MCC)
130
(CAF)
40 20
(MCC)
80 65
(CAF)
1-6 0-27
(VAP)
8-0 3 9
(CAF)
7-7
(VAP)
1300 270
(VAP)
MCC =MTX/CY/CCNU in combination.
CAF =CY/ADR/FU in combination.
VAP =VINCR/ADR/procarbazine in combination.
* Single agent at a maximum tolerated dose (MTD).
t Dose of single agent in MTD of a combination (in parentheses).
Schedule
3 divided doses in
24 h
single dose
single dose
single dose
0*8 mg/kg Days 1 +5
0-135 mg/kg Days 1+5
single dose
260 mg/kg o.d. x 5
54mg/kg o.d. x 5
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FIG. 1.-Dose response after treatment of 3 small-cell anaplastic-carcinoma xenografts with CY,
CCNU and MTX as single agents and in combination (MCC). Response is expressed as growth
delay; i.e. multiples of the median volume-doubling time of untreated control tumours. Shown in
the upper panels are individual tumours which completely regressed and failed to regrow after
treatment at various dose levels. (a) HX29. (b) HX78. (e) HX69.
RESULTS
Chemotherapy of small-cell carcinoma xeno-
grafts with MCC
Three small-cell carcinoma xenografts
were treated (HX29, HX69 and HX78).
Each line was serially transplantable,
produced high take rates (70-100%) and
grew relatively rapidly (mean tumour
volume-doubling times 5-9 days). Donor
patients of HX29 and HX78 received no
chemotherapy. The donor of HX69 re-
ceived MCC but died before objective
assessment of response. Therefore, no
chemotherapeutic data on these donor
patients are available for comparison with
respective xenograft responses.
Fig. l(a) shows the dose-response rela-
tionships obtained after treatment of
HX29 with the MCC combination and
component single agents individually.
Treatment with CY produced a linear dose
response, which implies an exponential
relationship for clonogenic cell kill
(Stephens & Peacock, 1977). A similar dose
response was obtained with CCNU, though
there was some evidence of a threshold at
the lower end of the curve, such that no
tumour growth delay could be seen below
25% of the MTD. In contrast, the small
growth delay produced by MTX remained
unchanged from low dose (10% MTD) to
extremely high dose (200% MTD) in those
animals remaining alive after treatment in
the latter case. This is in keeping with
plateau-type cell-survival curves reported
with MTX (Bruce et al., 1969).
When these agents were combined
(MCC) an almost linear dose response was
obtained, though a small threshold effect
TABLE II.-Response to treatment ofsmall-
cell anaplastic-carcinoma xenografts with
combinationsandcomponentsingle agents
at MTD
Growth d0Jayt
Xeno-
graft
(a)
HX78
HX69
HX29
(b)
HX78
HX29
Combination Single agents
A
MCC CY CCNU MTX
9 0 9.0* 5-9 0 5
10-7* 6-6 3-4 0 3
7-8 3-1 3-4 1-2
_
VAP VINCR ADR PROCARB
4-5 3-0 1-2 18.8*
2-2 1-3 0.1 10-3
* Values obtained by extrapolation of dose-
response curve when substantial numbers of tumours
failed to regrow.
t Multiples of the median volume-doubling time
ofcontrol tumours.
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was present at low doses. At the MTD a
substantial growth delay was achieved.
Similar dose-response relationshipswere
obtained in HX78 (Fig. lb) and HX69
(Fig. lc). These xenografts appeared
generally more responsive to CY and
CCNU than HX29, though MTX was
ineffective in both. Growth delays after
treatment with the MTD of these agents,
singly and in combination, are shown in
Table 11(a). In contrast to HX29, substan-
tial numbers of permanent xenograft
regressions were obtained after treatment
ofHX78 and HX69 with CY and MCC. In
HX69 the MTD of MCC produced com-
plete regressions inallthe treatedtumours.
A theoretical growth delay of 107,
obtained by extrapolation of the MCC
dose-response curve to the MTD, would
normally have delayed regrowth of drug-
controlled tumours for more than 2
months. However, the chronic toxicity of
CY caused wasting and death of mice
about 2 months after treatment. The
documented long-term regressions may
therefore not represent true "cures".
Many tumours were unexpectedly con-
trolled by lower doses of CY and MCC in
xenograft HX78, despite the fact that the
growth delays achieved in those tumours
that regrew in the same treatment groups
were not large. A similar phenomenon was
previously reported by Kopper & Steel
(1975) and is thought due to returning host
immunity in a proportion of immune-
suppressed anmals.
Chemotherapy of small-cell carcinoma xeno-
grafts with VAP
Two xenografts, HX29 and HX78, were
treated. Growth delays produced by
agents comprising VAP, used alone and in
combination at MTD are shown in Table
11(b).
Fig. 2(a) shows that procarbazine pro-
duced a linear dose response in HX29.
Sporadic permanent regressions were seen
at each dose level. Longer growth delays
were produced by the same agent in HX78
(Fig. 2b). A growth delay of - 10 volume-
doubling times achieved by 50% MTD
TABLE III. The relationship of reponse
(median growth delay) to the proportion of
tumours in each experimental group of
small-cell anaplastic carcinoma xeno-
grafts which were "controlled" by treat-
ment (datafrom 10 xenograft lines)
Median Controlledt Total
growth delay* tumours tumours %
0-1*9 8 197 4-1
2-0-3-9 21 122 17-2
4 0-5-9 11 40 27-5
6-0-7-9 33 74 44-6
8-0-9-9 9 13 69-2
10-0-11-9 36 43 83-7
> 12-0 30 32 93-8
* Obtained by extrapolation of dose-response
curve where necessary.
t "Control" indicates complete regression with
failure to regrow (luring the experiment (3-9
months).
equalled the effect ofthe MTD ofprocarb-
azine in HX29. The MTD of procarbazine
in HX78 achieved complete tumour con-
trol. In contrast to CY, procarbazine did
not produce chronic toxicity. It was
therefore possible to observe the animals
for 6 months after treatment. Tumour
regrowth would have been demonstrable
during this long observation period, indi-
cating the possibility of either genuine
tumour cure by the treatment or sub-
stantial host rejection.
In tumour lines HX29 and HX78, the
responses to the MTD of VAP relative to
procarbazine were small, because the dose
of procarbazine within the combination
was only 250% of the MTD of that agent,
due to dose-selection criteria. Combination
doses ofVINC and ADR, both found to be
much less effective in the xenografts, were
relatively higher.
Complete tumour regression: calculation of
extrapolated growth delay
Complete regression, with or without
tumour regrowth, was frequently seen in
the small-cell carcinoma xenografts
treated with CY, CCNU or procarbazine.
Extrapolation of the dose-response curve
allowed calculation of the GD that might
have been observed at MTD had there
been no tumour control. Such values are
hypothetical, but allow the response ofthe
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I'mr. 2.-Dose response after' treatmeInt of 2 small-cell aniaplastic carcinoma xenogiafts with VINCR.
AI)R andi procarbazine (PROCARB) as single agents andt in combination (VAP). Response is
expressed as grow%thldelay, i.e. multiples of the me(lian volume-doubling time of untreate(d control
tumouirs. Shown in tfle tipper panels are individual tumours wlhich completely regresse(l an(l
failedt to regrow% after treatment at valiouis (lose levels. (a) HXX29. (b) HX78.
tumours to be ranked. Shown in Table II1
are data derived from treatment of 10
different small-cell carcinoma xenografts
(including HX29, HIX69 and HX78). The
chemotherapeutic response of individual
tumours which regrew appears to be
linearly related to the proportion of
controlled tumours in each experimental
group.
Chemotherapy of non-small-cell carcinomaea
venografts wvith CAF
Two large-cell anaplastic (HX65, HX82)
and 3 adenocarcinoma xenografts (HX70,
HX83, HX87) were treated. Each line was
serially transplantable with mean tumour-
volumedoublingtimes of 2-10 days. Donor
patients of HX70, HX82 and HX83 were
treated with CAF and each failed to
respond. The other 2 donor-patients re-
ceived no chemotherapy.
Table IV shows that the growth delays
after treatment of the xenografts with
CAF were universally poor. Improved
responses were not obtained by raising the
dose of each individual agent to its MTD.
Statistical analysis ofthe results ofxenograft
chemotherapy
MCC and component agents (Table
lIa). The effectiveness of similar treat-
ments in HX29, HX78 and HX69 did not
differ significantly (P- 0 60). However,
there were significant differences in the
magnitude of response to different agents
used to treat the same tumour (P - 0 03).
The MCC combination was more effective
than any of the single components.
VAP and component agents (Table
JIb).-Only 2 xenografts (HX29, HX78)
were available for analysis. Procarbazine
clearlv stood out as the most effective
agent.
CAF and component agents (Table IV).-
There were no significant differences
beween the effectiveness of agents when
used alone at MTD, alone at the combina-
tion dose, or combined in CAF (P - 0 44).
This contrasts with the MCC results.
Although the non-small-cell carcinoma
xenografts were all chemoresistant, some
small differences were observed in relative
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TABLEIV.-Response to treatment of large-cell-anaplastic and adenocarcinoma
xenografts with CY, ADR and FU in combination (CAF) and as single agents
Growth delayt
CY
Xenograft CAFt 200 mg/kgt 130 mg/kg4
HX65 0-6 1-0 0-6*
HX70 0 0 0
HX82 1-7 2-0 1-0
HX83 1-6 0 4 0-9
HX87 0 0 0
ADR
8 0 mg/kgt 3.9 mg/kgl
0-5 0
0-1 0
0-3 0
0-9 0.1
0 0
FU
80 mg/kgt 65 mg/kg4
0.9* 0.7*
0.5 0-7
1.1 1-9
0-2 0
0 0
* Interpolated values using dose-response curve.
t MTD.
t Dose used in CAF.
In multiples of the median volume-doubling time of control tumours.
TABLE V.-Effect of treatment of bronchial-carcinoma xenografts with MTDs
of various single agents
Growth delay
Tumour type
Small-cell
Small-cell
Large-cell
Adeno
Xenograft
HX78
HX29
HX65
HX70
Procarb
18-8
10-3
1-6
0-8
CY
9-0
3-1
1-0
0
CCNU
5-9
3 -4
2-2
0-3
VINCR
3-0
1-3
1*1
0-2
ADR
1-2
0-1
0-5
0-1
MTX
0-5
1-2
0-4
0
chemosensitivity from line to line (P
0.008).
The effectiveness of procarbazine, cyclo-
phosphamide and CCNU in small-cell
carcinoma (Table V).-Significant differ-
ences in drug effectiveness were found in
small-cell carcinoma xenografts (P
0-008), procarbazine, CCNU and CY pro-
ducing the best responses. Resistance of
non-small-cell carcinoma xenografts to
agents effective in small-cell carcinoma
was also significant (P < 0.004).
DISCUSSION
Three triple-drug combinations used in
the treatment of patients with bronchial
carcinoma at the Royal Marsden Hospital
have been examined experimentally.
Large growth delays with complete
tumour control at the MTD in small-cell
carcinoma xenografts receiving MCC com-
bination chemotherapy are consistent with
recent clinical results in which significant
increases in objective response and pro-
longation of survival have been docu-
mented (Bunn et al., 1977; Bunn & Ihde,
1981). In contrast, large-cell anaplastic
and adenocarcinoma xenografts were all
resistant to CAF combination chemo-
therapy, in keeping with the poor clinical
responses to this regime, recently des-
cribed by Brugarolas et al. (1979) and
Taylor et al. (1980).
Single-agent clinical studies in small-
cell carcinoma have demonstrated the
effectiveness of procarbazine, CY and
CCNU (Selawry, 1977). Complete regres-
sions have been obtained with the latter
2 agents. Excellent responses to these
drugs were also seen in the small-cell
carcinoma xenografts.
However, host factors in the mouse may
be important determinants of tumour
response to chemotherapy (Kopper &
Steel, 1975; Steel et al., 1980). About 60%
of thymectomized, Ara-C-pretreated mice
begin to lose their receptivity to xeno-
grafts 5-6 weeks after whole-body irradia-
tion (Phelps et al., 1980). It is therefore
necessary to consider the possibility of
artefacts due to host defences, especially
when comparing drugs that differentially
suppress host immunity. The effects of
returning host immunity may be apparent
Cell
type
Large
Adeno
Large
Adeno
Adeno
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only after substantial reduction in tumour
mass. It could be that whilst chemo-
therapy kills a proportion of cells, induced
immunity deals with a fixed number,
dependent on the immune status of the
host (Skipper & Schabel, 1973; Porteous et
al., 1979). As a tumour regresses the
apparent effect ofhost immunity therefore
increases. This would explain the present
results, in which a relatively small growth
delay was sometimes accompanied by
anomalous cures in some animals, while
untreated control tumours continued to
grow. The effects ofhost defence stress the
need for caution in the interpretation of
complete xenograft control by experi-
mental chemotherapy. Nevertheless, it has
been clearly shown in this study that
growth delay increases with the proba-
bility of tumour control, implying a
considerable chemotherapeutic effect over
and above any artefacts produced by host
defence.
There have been very few previous
reports confirming linear dose responses in
chemosensitive human tumours. Their
significance, demonstrated in the xeno-
grafts, is the clinical potential ofexploring
the effect ofescalating the CY dose beyond
that now considered to be high (1.5 g/m2)
by the simultaneous use of marrow
autografts (Souhami, personal communi-
cation). Therapeutic response might there-
fore be improved, though dose limitation
would then depend on gut and bladder
toxicity.
The superiority of procarbazine in the
xenografts is interesting. In patients, dose-
limiting toxicity usually arises from
nausea and vomiting, and since the drug
is administered orally, it is frequently not
tolerated. This factor may have adversely
masked its true potential in clinical trials.
There is clearly a strong indication for the
pursuit of analogues which can be better
tolerated by systemic administration.
However, with the distinct possibility of
long-term remission in patients with small-
cell carcinoma, the oncogenic potential of
procarbazine itself must not be overlooked
(Spivack, 1974).
An unexpected finding was the resist-
ance of xenografts to MTX and ADR,
since the documentation of complete
responses clinically to both agents indi-
cates theirpotentialeffectiveness (Selawry,
1977; Livingston, 1978; Ettinger et al.,
1979). However, there is no convincing
evidence that as single agents they have
prolonged the median survival of patients
in either small-cell or non-small-cell car-
cinomas. Resistance in the xenografts may
reflect pharmacodynamic differences be-
tween man and mouse. Although some
reponse to MTX and ADR might have
been expected on the basis of clinical
studies, the possiblity of the chance
selection of a panel ofresistant xenografts
cannot be excluded.
The ranking of drug effectiveness was
similar amongst the 3 small-cell carcinoma
xenografts, but there was some evidence
for individuality of response to CY and
CCNU, though the observations are too
few for firm conclusions. CY was more
effective than CCNU in 2/3 tumour lines.
Furthermore, complete tumourregressions
without regrowth have been found in a
fourth small-cell carcinoma xenograft line
(HX76) in response to the MTD ofCCNU.
An equitoxic dose of CY was relatively
ineffective (Growth Delay 1-3) in the same
xenograft.
The possibility that xenografts of the
same-cell type display individualitv in
their response is an important but largely
unanswered question. If this proves to be
correct, this would be a strong indication
for the use of xenografts to screen for
chemosensitivity of individual donor
patients in a predictive capacity. In the
case of disseminated or inoperable bron-
chial carcinoma, this is not practical. It
has been found in this study that only 4/32
patients with metastatic disease from
whom xenografts were established sur-
vived long enough for predictive studies to
beuseful.Theonlyrealistichopesatpresent
are in vitro chemosensitivity tests (Salmon
et al., 1978) or the in vivo subrenal-capsule
system recently described by Bogden et al.
(1978). Both techniques require urgent
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and independent validation before their
widespread use is justified.
There is a case for the incorporation of
serially transplantable lung-tumour xeno-
grafts into primary drug screening pro-
grammes, to compliment the existing
syngeneic rodent tumours (Goldin et al.,
1981). Single examples of each histological
type are clearly insufficient to allowfor in-
dividualityofresponse. Different cell types
may show varying individuality, making
the ideal number of histologically similar
xenografts for effective screening difficult
to gauge. A more detailed study of this
problem is indicated.
We would like to thank Mrs Annabel Thomas for
her efficient secretarial help, Mr Ted Merryweather
who immune-suppressed the mice, and Mr David
Randall for his high standard of animal care.
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